Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
AAPG
$25.02
$
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Next Earnings
2026-02-25
Beta
0.883
Average Volume
Market Cap
Last Dividend
CIK
0002023311
ISIN
US04390B1052
CUSIP
04563G101
CEO
Dajun Yang
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
567
IPO Date
2025-01-24
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript | Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript | Seeking Alpha | 2026-02-12 17:14:26 |
| Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Rating of “Buy” by Analysts | Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ: AAPG - Get Free Report) have been given a consensus rating of "Buy" by the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy | Defense World | 2026-02-08 04:30:56 |
| Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 | ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its novel next-generation Bruton's tyrosine kinase (BTK)-targeted protein degrader, APG-3288, has received investigational new drug (IND) application clearance from the China Center for Drug Evaluation (CDE) and is poised to enter a clinical study in patients with relapsed/refractory hematologic malignancies. This IND clearance from the China CDE, which came shortly after the IND was cleared by the U.S. Food and Drug Administration (FDA), ushers in a new phase in the multicenter clinical development of APG-3288 and highlights Ascentage Pharma's robust global development capabilities in the field of targeted protein degradation. | GlobeNewsWire | 2026-02-05 18:30:00 |
| Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest | Ascentage Pharma Group International - Unsponsored ADR (NASDAQ: AAPG - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 745 shares, an increase of 102.4% from the December 31st total of 368 shares. Based on an average daily | Defense World | 2026-01-30 01:22:54 |
| Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-15 00:16:01 |
| Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference | ROCKVILLE, Md. and SUZHOU, China, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its Chairman and CEO, Dajun Yang, M.D., Ph.D., presented at the 44th Annual J.P. Morgan Healthcare Conference. In the corporate presentation, Dr. Yang provided an overview of milestone achievements in 2025 and outlined the Company's global innovation strategy for 2026. | GlobeNewsWire | 2026-01-14 20:25:00 |
| ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% | ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the first dataset from the global registrational Phase III study (POLARIS-1) of the company's novel, investigational drug, Olverembatinib (HQP1351), in combination with low-intensity chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. | GlobeNewsWire | 2025-12-08 19:45:00 |
| ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP | ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented four year follow-up data from its randomized controlled, registrational Phase II study of Olverembatinib in patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. Building on results released in an oral presentation at ASH 2023, these data reaffirm Olverembatinib's differentiated long-term efficacy and safety. | GlobeNewsWire | 2025-12-08 19:45:00 |
| ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment | ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the latest data on Olverembatinib, the Company's novel drug, in second-line treatment of patients with chronic myeloid leukemia (CML) in chronic-phase (-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. This presentation provided an update on the results released in an oral presentation at ASH 2024 and featured data from a longer follow-up on efficacy and safety. | GlobeNewsWire | 2025-12-08 19:45:00 |
| ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances | ROCKVILLE, Md. and SUZHOU, China, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax (APG-2575), a key investigational drug candidate in the Company's pipeline, in combination with azacitidine (AZA) in patients with newly diagnosed or prior venetoclax–exposed myeloid malignancies in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. | GlobeNewsWire | 2025-12-07 20:10:00 |
| Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented an oral report featuring the latest results from a registrational Phase II study conducted in China of Lisaftoclax (APG-2575), a key drug candidate in the Company‘s pipeline, as a monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis), at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, FL. Data from this pivotal trial supported the NDA approval that was granted to Lisaftoclax by China's National Medical Products Administration (NMPA) in July 2025. | GlobeNewsWire | 2025-12-06 10:15:00 |
| Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA | ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct a global registrational Phase III study (POLARIS-1; NCT06051409 ) of its compound under investigation, olverembatinib, in combination with chemotherapy for the treatment of newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). As the second global registrational Phase III study of olverembatinib that has been cleared by regulators in the US and Europe, the POLARIS-1 study is simultaneously enrolling patients across trial centers in multiple countries in order to accelerate olverembatinib's path to registration worldwide, particularly in the US and European markets. | GlobeNewsWire | 2025-12-04 19:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 6-K | 2026-02-23 | 2026-02-23 | View Filing |
| 6-K | 2026-02-09 | 2026-02-09 | View Filing |
| 6-K | 2026-02-06 | 2026-02-06 | View Filing |
| 6-K | 2026-01-15 | 2026-01-15 | View Filing |
| 6-K | 2026-01-07 | 2026-01-07 | View Filing |
| 6-K | 2025-12-31 | 2025-12-31 | View Filing |
| 6-K | 2025-12-17 | 2025-12-17 | View Filing |
| 6-K | 2025-12-09 | 2025-12-09 | View Filing |
| 6-K | 2025-12-08 | 2025-12-08 | View Filing |
| 6-K | 2025-12-05 | 2025-12-05 | View Filing |
| 6-K | 2025-12-01 | 2025-12-01 | View Filing |
| 6-K | 2025-11-28 | 2025-11-28 | View Filing |
| 6-K | 2025-11-25 | 2025-11-25 | View Filing |
| 6-K | 2025-11-19 | 2025-11-19 | View Filing |
| 6-K | 2025-11-04 | 2025-11-04 | View Filing |
| 6-K | 2025-10-30 | 2025-10-30 | View Filing |
| 6-K | 2025-10-07 | 2025-10-07 | View Filing |
| S-8 | 2025-09-16 | 2025-09-16 | View Filing |
| S-8 POS | 2025-08-28 | 2025-08-28 | View Filing |
| 6-K | 2025-08-28 | 2025-08-28 | View Filing |
| 6-K | 2025-08-21 | 2025-08-21 | View Filing |
| 6-K | 2025-08-18 | 2025-08-18 | View Filing |
| 6-K | 2025-08-08 | 2025-08-08 | View Filing |
| 6-K | 2025-08-07 | 2025-08-07 | View Filing |
| 6-K | 2025-08-01 | 2025-07-31 | View Filing |
| 6-K | 2025-07-25 | 2025-07-25 | View Filing |
| 6-K | 2025-07-17 | 2025-07-17 | View Filing |
| 6-K | 2025-07-15 | 2025-07-14 | View Filing |
| 6-K | 2025-07-10 | 2025-07-10 | View Filing |
| 6-K | 2025-07-08 | 2025-07-08 | View Filing |
| 6-K | 2025-06-27 | 2025-06-27 | View Filing |
| 6-K | 2025-06-16 | 2025-06-16 | View Filing |
| 6-K | 2025-06-10 | 2025-06-09 | View Filing |
| 6-K | 2025-06-03 | 2025-06-02 | View Filing |
| 6-K | 2025-05-23 | 2025-05-23 | View Filing |
| 6-K | 2025-05-20 | 2025-05-20 | View Filing |
| 6-K | 2025-04-28 | 2025-04-28 | View Filing |
| 6-K/A | 2025-04-24 | 2025-04-24 | View Filing |
| 6-K | 2025-04-21 | 2025-04-21 | View Filing |
| 6-K | 2025-04-17 | 2025-04-16 | View Filing |
| 20-F | 2025-04-16 | 2025-04-16 | View Filing |
| 6-K | 2025-04-08 | 2025-04-08 | View Filing |
| 6-K | 2025-03-31 | 2025-03-31 | View Filing |
| 6-K | 2025-03-27 | 2025-03-27 | View Filing |
| 6-K/A | 2025-03-26 | 2025-03-26 | View Filing |
| 6-K | 2025-03-26 | 2025-03-25 | View Filing |
| 6-K | 2025-03-12 | 2025-03-12 | View Filing |
| 6-K | 2025-03-06 | 2025-03-05 | View Filing |
| 6-K | 2025-02-25 | 2025-02-25 | View Filing |
| 6-K | 2025-02-14 | 2025-02-14 | View Filing |
| 6-K | 2025-02-11 | 2025-02-10 | View Filing |
| SEC STAFF LETTER | 2025-01-24 | 2025-01-28 | View Filing |
| 424B4 | 2025-01-24 | 2025-01-24 | View Filing |
| S-8 | 2025-01-24 | 2025-01-24 | View Filing |
| EFFECT | 2025-01-24 | 2025-01-24 | View Filing |
| CERT | 2025-01-23 | 2025-01-23 | View Filing |
| CORRESP | 2025-01-21 | 2025-01-21 | View Filing |
| CORRESP | 2025-01-21 | 2025-01-21 | View Filing |
| 8-A12B | 2025-01-21 | 2025-01-21 | View Filing |
| F-1/A | 2025-01-21 | 2025-01-21 | View Filing |
| F-1 | 2024-12-27 | 2024-12-27 | View Filing |
| SEC STAFF LETTER | 2024-12-17 | 2024-12-17 | View Filing |
| DRS/A | 2024-12-10 | 2024-12-10 | View Filing |
| DRSLTR | 2024-09-13 | 2024-09-14 | View Filing |
| DRS/A | 2024-09-16 | 2024-09-14 | View Filing |
| UPLOAD | 2024-09-10 | 2024-09-10 | View Filing |
| DRSLTR | 2024-08-27 | 2024-08-27 | View Filing |
| DRS/A | 2024-08-27 | 2024-08-27 | View Filing |
| UPLOAD | 2024-08-15 | 2024-08-15 | View Filing |
| DRSLTR | 2024-07-31 | 2024-07-31 | View Filing |
| DRS/A | 2024-07-31 | 2024-07-31 | View Filing |
| UPLOAD | 2024-07-12 | 2024-07-12 | View Filing |
| DRS | 2024-06-14 | 2024-06-14 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Volume Gap | 19.84% | 1.02 | 205 | 0.11 | 0.14 | 27.7 |
| Larry Williams PercentR Strategy | 9.09% | 1.05 | 73 | 0.05 | 0.06 | 16.95 |
| Macd Rsi Composite Strategy | 8.03% | 0.99 | 5 | 0.24 | 0.41 | 15.9 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |